Evotec Shares in Holding Pattern Ahead of Key Report

Evotec shares hover near €4.50 ahead of April 8 annual report. Analysts diverge widely on price targets as market weighs restructuring costs and future savings.

Investors in Evotec SE are in a state of anticipation, with the stock trading in a narrow band around €4.50. The market is awaiting the definitive annual report for 2025, scheduled for release on April 8, which will provide granular details following a significant corporate restructuring and a tempered financial outlook.

Restructuring Costs and Future Savings

The biopharmaceutical company's strategic overhaul, now well-communicated to the market, involves cutting approximately 800 positions. This move is expected to incur restructuring charges in the vicinity of €100 million. Management projects that the efficiency drive will yield annualized cost savings of around €75 million starting in 2028.

For the 2026 fiscal year, Evotec's leadership has provided guidance for revenue to fall between €700 million and €780 million. This forecast sits below the preliminary figure of €788 million reported for 2025. Similarly, the adjusted EBITDA is anticipated to be in a range of zero to €40 million, compared to €41 million in the prior year. These projected steps backward on paper help explain the subdued share price action witnessed in recent weeks.

Divergent Views from Market Experts

A notable feature of the current analyst coverage is the exceptionally wide dispersion in price targets. This highlights a lack of consensus on the stock's fair value. On the conservative end, Deutsche Bank rates the shares a "Hold" with a target of €4.50, aligning exactly with the present trading level.

In stark contrast, analysts at Berenberg and RBC Capital Markets see substantially more upside. Berenberg has set a price objective of €9.70, while RBC's target is €10.00, accompanied by an "Outperform" rating. Both firms base their more optimistic assessments on the company's medium-term strategy, which is also championed by the newly appointed Chief Commercial Officer, Dr. Ashiq H. Khan.

From a technical perspective, chart analysts identify a crucial support zone between €3.995 and €4.01. This level was established by the lows recorded on March 13 and March 23.

April 8: The Crucial Catalyst

The upcoming publication of the full annual report on April 8 is set to be the next major catalyst for the equity. The critical question for the market is whether the final figures will simply confirm the already disclosed preliminary data or if operational details—particularly concerning margin progression and the tangible advancement of cost-reduction initiatives—will deliver surprises.

A material deviation from the provided guidance is likely to trigger significantly higher volatility. Until then, the €4.50 price level serves as a key short-term reference point for traders and investors alike.